Dr. Martens
Website:
Dr. Martens
Index:
FTSE 250
EPIC: DOCS
Supersector:
Personal and Household Goods
Sector:
Personal Goods
Subsector:
Footwear
Market Cap:
£600.24M
Payout Frequency: Semi-Annual
Dr. Martens Dividend Analysis and Summary
Headline Dividend Details
- Dividend declared: Interim dividend of 0.85p per share (unchanged vs prior-year interim)
- Ex-dividend date: 05/03/2026 (derived from the record date below)
- Record date: 06/03/2026
- Payment date: 09/04/2026
- Policy: payout of 25–35% of earnings; interim is set at one-third of the prior year’s total dividend (FY25 total: 2.55p; thus interim = 0.85p)
Quick Context
- H1 FY26 adjusted basic EPS: -0.9p (loss); statutory EPS: -1.0p
- Guidance: FY26 Adjusted PBT consensus £53m–£60m before tariffs; tariffs are a high single-digit £m headwind, with roughly half expected to be mitigated in-year
- Balance sheet: Net bank debt (ex-leases) £154.3m; total net debt (incl. leases) £302.3m; covenant leverage 2.1x vs <3.0x covenant
Assessment: Sustainability and Cover
- Near-term cover is thin: the interim is formulaic (one-third of last year’s total) and not covered by H1 earnings (adjusted loss per share).
- Full-year cover depends on a stronger H2. Management still targets positive FY26 adjusted profits despite tariff drag (partly mitigated), implying the final dividend will be flexed to align with the 25–35% payout range.
- FY25 reference point: adjusted EPS was 2.4p vs total dividend 2.55p, indicating tight historical coverage. Sustained dividend growth will require delivery on FY26–FY27 profit recovery.
- Cash and leverage: refinancing (to Nov-2027) and 2.1x leverage with covenant headroom support continuity, but net finance costs (c. £25m guided) and seasonality constrain flexibility.
Dividend Growth Trajectory
- Current move is flat: interim 0.85p, unchanged vs prior year.
- With H1 losses and tariff headwinds, scope for a higher final in FY26 looks limited. Medium-term ambition (mid-to-high-teens EBIT margin) could underpin growth from FY27 if execution continues and US tariff mitigation is fully realised.
Support from Financial Performance and Capital Allocation
- Strategy shift toward higher-quality revenue (full-price DTC up 6%) improved gross margin to 65.3%, aiding profit recovery despite lower clearance.
- Cost discipline and last year’s cost action plan support margin; capex guidance ~£20m and inventory broadly flat YoY are consistent with a cash-preserving stance that helps fund the regular dividend.
- Capital allocation framework remains intact: invest for growth first, then regular dividend, and further returns when possible. No buybacks flagged.
Structural/Policy Changes Relevant to Dividends
- No structural corporate actions (no demergers, M&A or share consolidation) announced.
- Debt facilities were refinanced in Nov-2024 (term loan to Nov-2027; RCF £126.5m), providing visibility and covenant headroom supportive of dividend continuity.
- US tariff impact expected to be fully mitigated from FY27 via cost control, sourcing and selective US pricing—supportive for medium-term dividend capacity.
Key Risks and Flags to Dividend Stability
- Earnings cover risk: H1 losses and tight FY25 cover increase reliance on a strong H2 to fund the final dividend within policy.
- Tariffs: FY26 headwind is only partially mitigated; execution risk until full mitigation in FY27.
- Regional softness: Variable trading in EMEA (retail particularly challenged) could pressure margins and cash generation.
- Macro/FX: FX headwind to revenue (~£10m) and consumer caution add uncertainty to H2.
- Financing costs/leverage: Net finance costs around £25m and leverage at 2.1x limit headroom if trading underdelivers.
- Seasonality/working capital: H1 outflow shows sensitivity; any peak-season miss could squeeze cash available for distributions.
Read more
Dr. Martens Annual Dividend Yield - 4.14%
Dividends Used in Calculation:
| Ex-Dividend Date |
Payment Date |
Type |
Amount |
Currency |
| 06/03/2025 |
08/04/2025 |
Interim |
0.85p |
GBX |
| 28/08/2025 |
08/10/2025 |
Final |
1.70p |
GBX |
Total (Annual Dividends Per Share):
2.55p
Dividend Yield =
Annual Dividends Per Share (2.55p)
÷ Share Price (61.65p)
= 4.14%
Dr. Martens Dividend History
| Ex Dividend Date |
Payment Date |
Type |
Amount |
Currency |
| 05/03/2026 |
09/04/2026 |
Interim |
0.8500p |
GBX |
| 28/08/2025 |
08/10/2025 |
Final |
1.70p |
GBX |
| 06/03/2025 |
08/04/2025 |
Interim |
0.85p |
GBX |
| 29/08/2024 |
01/10/2024 |
Final |
0.99p |
GBX |
| 04/01/2024 |
02/02/2024 |
Interim |
1.56p |
GBX |
| 08/06/2023 |
18/07/2023 |
Final |
4.28p |
GBX |
| 05/01/2023 |
03/02/2023 |
Interim |
1.56p |
GBX |
| 09/06/2022 |
19/07/2022 |
Final |
4.28p |
GBX |
| 13/01/2022 |
04/02/2022 |
Interim |
1.22p |
GBX |
| 13/01/2022 |
04/02/2022 |
Q2 |
1.22 |
|
| Year |
Interim |
Final |
Currency |
Total |
Change |
| 2024 |
1.560 |
0.990 |
GBX |
2.550 |
-56.330 |
| 2023 |
1.560 |
4.280 |
GBX |
5.840 |
-13.090 |
| 2022 |
1.220 |
4.280 |
|
6.720 |
|
Dr. Martens Dividend Calculator
Dr. Martens Dividend Growth
| Dividend Growth (1Y) |
38.59%
|
| Dividend CAGR (5Y) |
–
|
| Years of Growth |
–
|
| Payout Ratio |
115.69%
|
| Buyback Yield |
-4.49%
|
| Shareholder Yield |
-0.42%
|
| P/E Ratio (TTM) | 40.13 |
| Forward P/E | 13.23 |
| P/FCF | 4.13 |
| Earnings Yield | 2.55% |
| FCF Yield | 24.22% |
| ROE | 4.61% |
| ROCE | 9.77% |
| Profit Margin | 1.95% |
| Operating Margin | 8.51% |
| Gross Margin | 65.52% |